The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10322 malaria professionals are enjoying the free benefits of MalariaWorld today

artesunate

Open Access | Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects

December 23, 2009 - 21:47 -- Ingeborg van Schayk
Author(s): 
Beesan Tan, Himanshu Naik, In-Jin Jang, Kyung-Sang Yu, Lee E Kirsch, Chang-Sik Shin, J Carl Craft, Lawrence Fleckenstein
Reference: 
Malaria Journal 2009, 8:304 (18 December 2009)

The population pharmacokinetics of artesunate (AS) and its active metabolite dihydroartemisinin (DHA) were studied in healthy subjects receiving single- or multiple-dosing of AS orally either in combination with pyronaridine (PYR) or as a monotherapy with or without food.

Technology: 

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines.

November 18, 2009 - 12:56 -- Kabogo Ndegwa
Author(s): 
Martin Michaelis, Malte C. Kleinschmidt, Susanne Barth, Florian Rothweiler, Janina Geiler, Rainer Breitling, Bernd Mayer, Hedwig Deubzer, Olaf Witt, Jörg Kreuter, Hans Wilhelm Doerr, Jaroslav Cinatl, Jindrich Cinatl Jr.
Reference: 
Biochemical Pharmacology, Volume 79, Issue 2, 15 January 2010, Pages 130-136, doi:10.1016/j.bcp.2009.08.013

Artemisinin derivatives are well-tolerated anti-malaria drugs that also exert anti-cancer activity. Here, we investigated artemisinin and its derivatives dihydroartemisinin and artesunate in a panel of chemosensitive and chemoresistant human neuroblastoma cells as well as in primary neuroblastoma cultures.

Medical Condition: 
Medical Treatment: 

Review: Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester

October 25, 2009 - 16:56 -- Bart G.J. Knols
Author(s): 
Robert L. Clark
Reference: 
Reproductive Toxicology, Volume 28, Issue 3, November 2009, Pages 285-296, doi:10.1016/j.reprotox.2009.05.002

Single oral doses of artesunate, dihydroartemisinin, arteether and artemether administered to rats during a sensitive period of organogenesis caused embryo deaths and malformations (malformed long bones and ventricular septal defects). Extended oral dosing (12 days or more) of monkeys once daily with 12 mg/kg-d artesunate also caused embryo deaths. The initial embryotoxic effect in both species was to kill primitive erythroblasts which are present in the embryo for a few days of gestation in rats and several weeks in primates.

 

Technology: 
Medical Condition: 

Pages

Subscribe to RSS - artesunate